放疗联合免疫治疗在晚期老年非小细胞肺癌患者中的应用价值
CSTR:
作者:
作者单位:

(1.四川大学华西医院肿瘤科,成都 610000;2.凉山彝族自治州第一人民医院肿瘤科,四川 西昌 615000)

作者简介:

通讯作者:

中图分类号:

基金项目:

四川省自然科学基金(2022NSFSC1465)


Application value of radiotherapy combined with immunotherapy in elderly patients with advanced non-small cell lung cancer
Author:
Affiliation:

(1.Department of Oncology, West China Hospital, Sichuan University, Chengdu 610000, China;2.Department of Oncology, First People′s Hospital of Liangshan Yi Autonomous Prefecture, Xichang 615000, Sichuan Province, China)

Fund Project:

This work was supported byNatural Science Foundation of Sichuan Province(2022NSFSC1465).

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的分析放疗联合免疫治疗在晚期老年非小细胞肺癌(NSCLC)患者中的应用价值。方法 选取2018年1月至2023年8月凉山彝族自治州第一人民医院收治的206例晚期老年NSCLC患者为研究对象。根据治疗方案,将患者分为免疫治疗组[程序性细胞死亡受体1(PD-1)免疫检查点抑制剂治疗,n=101]及联合治疗组[PD-1抑制剂联合容积旋转调强放射治疗(VMAT),n=105]。比较两组患者临床疗效、治疗前后T细胞亚群(CD4+、CD8+、CD4+/CD8+)、肺功能[第一秒用力呼气量(FEV1)、用力肺活量(FVC)、FEV1/FVC]及不良反应差异。采用SPSS 25.0统计软件进行数据分析。采用Kaplan-Meier生存曲线分析两组患者治疗后15个月无进展生存期(PFS)差异。结果联合治疗组患者客观有效率(50.48%和35.64%)及疾病控制率(81.90%和69.31%)均高于免疫治疗组(P<0.05)。两组患者治疗结束后CD4+、CD4+/CD8+与FEV1、FVC、FEV1/FVC均较治疗前升高(P<0.05),联合治疗组治疗后上述指标均高于免疫治疗组(P<0.05)。两组患者治疗不良反应发生率比较,差异均无统计学意义(均P>0.05)。以治疗15个月为终点,联合治疗组与免疫治疗组疾病进展率分别为30.48%(32/105)及48.51%(49/101)。Kaplan-Meier曲线分析显示,联合治疗组PFS中位数为12.41个月(95%CI 11.564~13.255),显著高于免疫治疗组的10.56个月(95%CI 9.576~11.553),差异有统计学意义(χ2=7.465,P=0.006)。结论VMAT联合PD-1抑制剂免疫治疗,不仅有助于提高晚期老年NSCLC患者临床疗效,且安全性良好,在改善患者免疫功能与肺功能、提升PFS方面均具有积极意义。

    Abstract:

    Objective To analyze the application value of radiotherapy combined with immunotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC). Methods A total of 206 elderly patients with advanced NSCLC admitted to the First People′s Hospital of Liangshan Yi Autonomous Prefecture from January 2018 to August 2023 were selected as the study subjects. According to the treatment regimens, the patients were divided into an immunotherapy group (n=101) treated with programmed cell death receptor 1 (PD-1) immune checkpoint inhibitors and a combination therapy group (n=105) treated with PD-1 inhibitors combined with volume rotation intensity modulated radiation therapy (VMAT). The two groups were compare in the clinical efficacy, T-cell subsets (CD4+, CD8+, CD4+/CD8+), pulmonary function [forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC] before and after treatment, and adverse reactions. SPSS 25.0 was used for data processing. Kaplan-Meier survival curves were used to analyze the difference in progression-free survival (PFS) at 15 months after the beginning of treatment in the two groups. Results The objective response rate (50.48% vs 35.64%) and disease control rate (81.90% vs 69.31%) in the combination therapy group were higher than those in the immunotherapy group (P<0.05). After the treatment, CD4+, CD4+/CD8+, FEV1, FVC and FEV1/FVC in both groups increased as compared with before treatment (P<0.05), and the above indicators in the combination therapy group after treatment were higher than those in the immunotherapy group (P<0.05). With 15 months of treatment as the end point, the disease progression rate was 30.48% (32/105) in the combination therapy group and 48.51% (49/101) in the immunotherapy group. Kaplan-Meier curve analysis showed that the median PFS of the combination therapy group [12.41 months (95%CI 11.564-13.255)] was significantly longer than that of the immunotherapy group [10.56 months (95%CI 9.576-11.553)], and the difference was statistically significant (Log-rank χ2=7.465, P=0.006). Conclusion VMAT combined with PD-1 inhibitor immunotherapy not only helps enhance the clinical efficacy in elderly patients with advanced NSCLC with good safety but also has positive significance in improving immunity function and pulmonary function and increasing PFS.

    参考文献
    相似文献
    引证文献
引用本文

袁晓利,李杨,刘从明,黎启菊,王峰.放疗联合免疫治疗在晚期老年非小细胞肺癌患者中的应用价值[J].中华老年多器官疾病杂志,2026,25(2):97-101
DOI:10.11915/j. issn.1671-5403.2026.02.022

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2025-01-18
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2026-02-03
  • 出版日期:
文章二维码